Get the Stockscreener App
2.41
0.42%
0.01
After Hours:
2.41
Alzamend Neuro Inc stock is traded at $2.41, with a volume of 40,406.
It is up +0.42% in the last 24 hours and down -1.23% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$2.40
Open:
$2.41
24h Volume:
40,406
Relative Volume:
0.24
Market Cap:
$6.98M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.3604
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
+3.88%
1M Performance:
-1.23%
6M Performance:
-60.03%
1Y Performance:
-86.74%
1-Day Range:
$2.36
$2.42
1-Week Range:
$2.26
$2.45
52-Week Range:
$2.06
$18.72
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.41 | 7.38M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Is Alzamend Neuro Inc. meeting your algorithmic filter criteria2025 Major Catalysts & Smart Money Movement Alerts - Newser
Real time breakdown of Alzamend Neuro Inc. stock performanceWeekly Stock Summary & Daily Stock Trend Reports - Newser
What does recent volatility data suggest for Alzamend Neuro Inc.July 2025 PreEarnings & Real-Time Volume Surge Alerts - Newser
How to use a screener to detect Alzamend Neuro Inc. breakoutsNew Guidance & Verified Momentum Watchlists - Newser
Technical signs of recovery in Alzamend Neuro Inc.Risk Management & Weekly High Conviction Ideas - Newser
Will breakout in Alzamend Neuro Inc. lead to full recoveryJuly 2025 Technicals & Stepwise Entry/Exit Trade Alerts - Newser
Can swing trading help recover from Alzamend Neuro Inc. lossesDividend Hike & Real-Time Stock Movement Alerts - Newser
Key metrics from Alzamend Neuro Inc.’s quarterly dataTrade Entry Report & High Conviction Trade Alerts - Newser
Is this a good reentry point in Alzamend Neuro Inc.July 2025 Trends & Free Low Drawdown Momentum Trade Ideas - Newser
Multi factor analysis applied to Alzamend Neuro Inc.New Guidance & Verified Momentum Stock Watchlist - Newser
Will a bounce in Alzamend Neuro Inc. offer an exit2025 Investor Takeaways & AI Powered Market Entry Ideas - Newser
Will Alzamend Neuro Inc. bounce back from current supportMarket Growth Review & Growth-Oriented Investment Plans - Newser
Using flow based indicators on Alzamend Neuro Inc.Market Movers & Proven Capital Preservation Methods - Newser
Developing predictive dashboards with Alzamend Neuro Inc. dataBuy Signal & Weekly Stock Performance Updates - Newser
Visual trend scoring systems applied to Alzamend Neuro Inc.July 2025 Earnings & Reliable Entry Point Alerts - Newser
Using economic indicators to assess Alzamend Neuro Inc. potential2025 Short Interest & Risk Adjusted Buy and Sell Alerts - Newser
Tick level data insight on Alzamend Neuro Inc. volatility2025 Market WrapUp & Scalable Portfolio Growth Ideas - Newser
How hedge fund analytics apply to Alzamend Neuro Inc. stock2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Can machine learning forecast Alzamend Neuro Inc. recoveryEarnings Performance Report & Precise Swing Trade Entry Alerts - Newser
real time breakdown of alzamend neuro inc. stock performanceQuarterly Portfolio Summary & Growth Oriented Trading Recommendations - Newser
Chart based analysis of Alzamend Neuro Inc. trends2025 Earnings Impact & Capital Protection Trading Alerts - Newser
Can you recover from losses in Alzamend Neuro Inc.2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Price action breakdown for Alzamend Neuro Inc.Exit Point & Daily Stock Trend Reports - Newser
How to monitor Alzamend Neuro Inc. with trend dashboards2025 Winners & Losers & Weekly Consistent Profit Watchlists - Newser
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire Inc.
Sentiment analysis tools applied to Alzamend Neuro Inc.Watch List & Real-Time Buy Signal Alerts - Newser
relative strength of alzamend neuro inc. in sector analysisWeekly Volume Report & Real-Time Market Sentiment Reports - Newser
What to expect from Alzamend Neuro Inc. in the next 30 daysJuly 2025 Price Swings & Verified Trade Idea Suggestions - Newser
Alzamend Neuro, Inc. SEC 10-Q Report - TradingView
What technical models suggest about Alzamend Neuro Inc.’s comebackJuly 2025 Opening Moves & Consistent Profit Trade Alerts - Newser
key metrics from alzamend neuro inc.’s quarterly dataJuly 2025 Breakouts & Reliable Trade Execution Plans - Newser
Can Alzamend Neuro Inc. hit a new high this month2025 Analyst Calls & Weekly High Return Forecasts - Newser
How to recover losses in Alzamend Neuro Inc. stockJuly 2025 Closing Moves & Low Risk Investment Opportunities - Newser
Published on: 2025-09-10 00:51:48 - Newser
Will Alzamend Neuro Inc. continue its uptrendWatch List & AI Driven Stock Price Forecasts - Newser
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):